News | May 12, 2015

Long-Term Economic Data Shows Savings With Atherectomy in ORBIT II Trial

Diamondback 360 coronary orbital atherectomy system demonstrated one-year cost savings of up to $4,913 per patient

ORBIT II, Diamondback 360, CSI, SCAI 2015, atherectomy

May 12, 2015 — Cardiovascular Systems Inc. (CSI) featured two-year data from its ORBIT II study of the company’s Diamondback 360 coronary orbital atherectomy system (OAS) in a late-breaking presentation at the 2015 Society for Cardiovascular Angiography and Interventions (SCAI) conference. Diamondback 360 is a U.S. Food and Drug Administration (FDA)-approved atherectomy technology indicated for the treatment of severely calcified lesions.

CSI completed ORBIT II enrollment of 443 patients at 49 U.S. medical centers in November 2012. The pivotal study evaluated the safety and efficacy of the company’s orbital atherectomy technology in treating patients with de novo severely calcified coronary lesions. ORBIT II was the first investigational device exemption (IDE) study in history to evaluate this problematic subset of patients. In October 2013, CSI received premarket application (PMA) approval from the FDA to market Diamondback 360 as a treatment for severely calcified coronary arteries to facilitate stent delivery.

Jeffrey Chambers, M.D., of Metropolitan Heart and Vascular Institute, Minneapolis, highlighted new data that demonstrated a high freedom from major adverse cardiac events (MACE) rate, including target lesion revascularization (TLR) and target vessel revascularization (TVR), at two years for this difficult-to-treat patient population.

“ORBIT II two-year data further demonstrates the safety and efficacy of using CSI’s Diamondback 360 orbital atherectomy system to treat severely calcified coronary arteries,” said Chambers. “We have witnessed impressive clinical and economic benefits of using this device in a complex patient population that can be challenging to treat with traditional options. We also know now that using the coronary OAS device prior to stent treatment in severely calcified arteries yields durable, long-term results.”

Chambers presented the following two-year data:

Two-Year Freedom From:

MACE                                                80.6%


MI (CK-MB >3x ULN)*                    90.3%

Non Q-wave                                    91.2%

Q-wave                                            99.1%


TVR/TLR                                        91.9%

TVR                                                97.1%

TLR                                                93.8%


Cardiac Death                               95.7%

*Based on reported CK-MB >3X ULN

Long-term patient outcomes are critical to understanding rates of hospital readmission when evaluating cost savings for the treating institutions and overall healthcare system. The Diamondback 360 Coronary OAS has been associated with a shorter length of stay for patients when the device was used to treat severely calcified lesions to facilitate stent placement compared to treating without the Diamondback 360. The lower incidence of readmission and shorter length of stay provide an estimated cost savings of up to $4,913 per patient to the treating institution at one year following the procedure.

The OAS device offers value with an incremental cost effectiveness ratio (ICER) of $11,895 per life year gained, which is well under the $50,000 per quality-adjusted life year (QALY) threshold, to be considered “high value.”

For more information: www.csi360.com

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Overlay Init